ClinicalTrials.gg
RecruitingNCT07608367Updated Oct 1, 2026

A Single-Center Clinical Study to Evaluate the Efficacy and Safety of a Suture-Free Ophthalmic Hydrogel for Ocular Surface Tissue Adhesion

An interventional study of Suture-Free Ophthalmic Hydrogel for Ocular Surface Surgery in Cornea Disease, sponsored by Suxia Li. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Suxia Li · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2025, registered Apr 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Corneal Diseases with a site in China — 5 open to participants now, 5 under way, none of them phase 3. Corneal Diseases · China.

Started
2025
the only one that year
No phase
4 of 11
2 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
Suxia Li

Among the 11 studies in Corneal Diseases with a site in China, this one is the only one that started in 2025, is one of 4 with no phase, and was the 11th registered.

Corneal Diseases

219 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.

Browse Corneal Diseases studies →

Open to participants now

5 of the 11 studies in Corneal Diseases with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 33 Corneal Diseases studies recruiting now, 21 (64%) set no upper age limit and 5 (15%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Corneal Diseases with a site in China, or all of them as a file.
02

Study summary

When severe ocular surface lesions occur (e.g., pterygium, corneal ulcer, ocular surface burn, etc.), the currently clinically common surgical procedures such as conjunctival flap coverage, amniotic membrane transplantation, and keratoplasty are primarily fixed by suturing. However, suturing has numerous drawbacks. On the one hand, the suturing process causes additional mechanical damage to ocular surface tissues, triggers local inflammatory responses, and increases postoperative discomfort such as pain and foreign body sensation. Moreover, uneven suture tension is prone to cause conjunctival flap shrinkage or displacement, impairing the repair effect. On the other hand, postoperative suture irritation continuously activates fibroblast proliferation, leading to excessive deposition of subconjunctival collagen and the formation of dense scar tissue, which in turn compromises the stability of the ocular surface tear film and visual quality. This study intends to develop a suture-free ophthalmic hydrogel for conjunctival flap adhesion. By combining the natural biological activity of decellularized porcine corneal matrix with the photocrosslinking properties of GelMA, and integrating low-energy visible light (465nm) curing technology, the hydrogel enables rapid, firm, and suture-free adhesion of conjunctival flaps.

03

Conditions studied

  • Cornea Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with ocular surface diseases (e.g., pterygium, corneal ulcer, ocular surface burn, pseudopterygium, etc.) who need to undergo conjunctival flap adhesion, amniotic membrane transplantation, or keratoplasty.
  2. Aged 18 to 85 years old at the time of (regardless of gender).
  3. Able to provide written informed consent and voluntarily participate in the study.
  4. No severe systemic organic diseases, such as severe heart, liver, kidney diseases, and malignant tumors.

Exclusion criteria

Exclusion Criteria:

  1. A history of allergy to the components of the suture-free ophthalmic hydrogel (e.g., decellularized porcine corneal matrix, GelMA, etc.) or the drugs prescribed during the perioperative and postoperative observation periods (anesthetics, antibiotics, preparations, etc.).
  2. Patients with systemic infectious diseases (bacterial, fungal, positive for , and other viruses, etc.).
  3. Diabetic patients with poor blood glucose control ( ≥ 8.0%).
  4. Pregnant women, women who may be pregnant, or women planning to become pregnant during the clinical study.
  5. Patients who have participated in other clinical trials or studies within 1 month before obtaining .
  6. Other patients deemed unsuitable for the clinical study due to comorbidities.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Suture-Free Ophthalmic Hydrogel for Ocular Surface Tissue Adhesion Therapy

    A Single-Center Clinical Study

    Biological: Suture-Free Ophthalmic Hydrogel for Ocular Surface Surgery

Interventions

  • BiologicalSuture-Free Ophthalmic Hydrogel for Ocular Surface Surgery

    Surgical treatment with hydrogel

06

What researchers measure

Primary outcomes

  1. Safety Evaluation Items

    Observation of ocular surface irritation symptoms (foreign body sensation, pain, photophobia, lacrimation, etc.), immunogenicity, sensitization, elevated intraocular pressure (IOP), ocular infection, conjunctival hyperemia, and other conditions.

    Time frame: 1 month postoperatively

Secondary outcomes

  1. Conjunctival flap adhesion effect

    The fitting status of the conjunctival flap was observed under a slit-lamp microscope to assess the presence of displacement or detachment, and the time of complete conjunctival flap adhesion was recorded.

    Time frame: 1st day, 1st week, and 1st month postoperatively

  2. Ocular surface repair status

    The changes in conjunctival flap thickness were examined by anterior segment optical coherence tomography (OCT), and the conjunctival epithelial healing was observed; fluorescein staining was used to evaluate the integrity of the ocular surface epithelium, and the time of complete epithelial coverage was recorded.

    Time frame: 1st week and 1st month postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2027, 15 months after the start.

Of 37 non-industry interventional studies with no phase under Corneal Diseases, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 54. This study's planned 15 months is below that.

Counting every sponsor, half of 43 studies reached it within 22 months; a quarter within 5 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start May 2026 → Oct 2025 and completion Jun 2027 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
May 27, 2026
StartActual
Oct 1, 2025was May 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027was Jun 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
Shandong Eye Hospital is now Recruiting
Oct 1, 2026
Start date
May 22, 2026→Oct 1, 2025 (actual)
Oct 1, 2026
Study completion
Jun 1, 2027→Jan 1, 2027
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    Shandong Eye Hospital is now Recruiting
    Start date May 22, 2026→Oct 1, 2025 (now actual)
    Study completion Jun 1, 2027→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07608367
Lead sponsor
Suxia Li
Responsible party
Suxia Li (Prof., Shandong Eye Hospital) — Sponsor-investigator
First posted
May 27, 2026
Start date
Oct 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Suxia Lo
Contact
lsuxiasusu@163.com
+86 158 5410 7085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion